MDT-AP-0578
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 59.04
- os_event
- false
- age_years
- 4
- sex
- F
- new_clusters
- C3
- umap1_2d
- 6.297759048
- umap2_2d
- 3.360938472
- umap1_3d
- 2.971368341
- umap2_3d
- -2.93783975
- umap3_3d
- -3.109433788
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.300
- WNT_BETA_CATENIN_SIGNALING+0.170
- DNA_REPAIR+0.130
- MYC_TARGETS_V2+0.120
- APICAL_JUNCTION+0.100
- PEROXISOME+0.070
- ADIPOGENESIS+0.050
- NOTCH_SIGNALING+0.050
- HEME_METABOLISM+0.010
- PI3K_AKT_MTOR_SIGNALING+0.010
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.430
- INTERFERON_ALPHA_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.400
- ANGIOGENESIS-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- COMPLEMENT-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- INTERFERON_GAMMA_RESPONSE-0.370
- COAGULATION-0.360
- KRAS_SIGNALING_UP-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1357 | Med | Medulloblastoma | 0.949 |
| 2 | MDT-AP-1120 | Med | Medulloblastoma | 0.927 |
| 3 | MDT-AP-0038 | Med | Medulloblastoma | 0.924 |
| 4 | MDT-AP-0550 | Med | Medulloblastoma | 0.908 |
| 5 | MDT-AP-1134 | Med | Medulloblastoma | 0.903 |
| 6 | MDT-AP-1345 | Med | Medulloblastoma | 0.902 |
| 7 | MDT-AP-0350 | Med | Medulloblastoma | 0.897 |
| 8 | SRR1318407 | GTEX | — | 0.896 |
| 9 | SRR604146 | GTEX | — | 0.895 |
| 10 | SRR1489054 | GTEX | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |